BNP Paribas Financial Markets’s Pacira BioSciences PCRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.51M | Buy |
59,385
+42,034
| +242% | +$994K | ﹤0.01% | 3030 |
|
|
2026
Q1 | $392K | Sell |
17,351
-94,126
| -84% | -$2.09M | ﹤0.01% | 3716 |
|
|
2025
Q4 | $2.89M | Buy |
111,477
+28,267
| +34% | +$672K | ﹤0.01% | 2400 |
|
|
2025
Q3 | $2.14M | Buy |
83,210
+63,564
| +324% | +$1.56M | ﹤0.01% | 2567 |
|
|
2025
Q2 | $470K | Sell |
19,646
-146,874
| -88% | -$3.7M | ﹤0.01% | 3362 |
|
|
2025
Q1 | $4.14M | Sell |
166,520
-55,219
| -25% | -$1.32M | ﹤0.01% | 1932 |
|
|
2024
Q4 | $4.18M | Sell |
221,739
-173,956
| -44% | -$3.05M | ﹤0.01% | 1900 |
|
|
2024
Q3 | $5.96M | Buy |
395,695
+288,662
| +270% | +$4.94M | ﹤0.01% | 1409 |
|
|
2024
Q2 | $3.06M | Buy |
107,033
+19,097
| +22% | +$544K | ﹤0.01% | 1668 |
|
|
2024
Q1 | $2.57M | Buy |
87,936
+1,444
| +2% | +$44.4K | ﹤0.01% | 1892 |
|
|
2023
Q4 | $2.92M | Sell |
86,492
-15,870
| -16% | -$464K | ﹤0.01% | 1718 |
|
|
2023
Q3 | $3.14M | Sell |
102,362
-9,206
| -8% | -$332K | ﹤0.01% | 1591 |
|
|
2023
Q2 | $4.47M | Buy |
111,568
+79,844
| +252% | +$3.3M | 0.01% | 1292 |
|
|
2023
Q1 | $1.29M | Buy |
31,724
+20,141
| +174% | +$801K | ﹤0.01% | 2146 |
|
|
2022
Q4 | $447K | Buy |
+11,583
| New | +$564K | ﹤0.01% | 2651 |
|
|
2022
Q3 | – | Sell |
-12,194
| Closed | -$711K | – | 4962 |
|
|
2022
Q2 | $711K | Sell |
12,194
-6,758
| -36% | -$443K | ﹤0.01% | 2440 |
|
|
2022
Q1 | $1.45M | Sell |
18,952
-10,489
| -36% | -$699K | ﹤0.01% | 2067 |
|
|
2021
Q4 | $1.77M | Sell |
29,441
-13,260
| -31% | -$731K | ﹤0.01% | 2144 |
|
|
2021
Q3 | $2.39M | Buy |
42,701
+27,238
| +176% | +$1.57M | ﹤0.01% | 1760 |
|
|
2021
Q2 | $938K | Buy |
15,463
+6,874
| +80% | +$435K | ﹤0.01% | 2219 |
|
|
2021
Q1 | $602K | Sell |
8,589
-1,092
| -11% | -$78K | ﹤0.01% | 2464 |
|
|
2020
Q4 | $579K | Sell |
9,681
-1,647
| -15% | -$96.4K | ﹤0.01% | 2378 |
|
|
2020
Q3 | $681K | Buy |
11,328
+7,756
| +217% | +$451K | ﹤0.01% | 2021 |
|
|
2020
Q2 | $187K | Sell |
3,572
-191,365
| -98% | -$8M | ﹤0.01% | 2518 |
|
|
2020
Q1 | $6.54M | Buy |
194,937
+184,755
| +1,815% | +$7.67M | 0.01% | 852 |
|
|
2019
Q4 | $461K | Buy |
10,182
+2,871
| +39% | +$122K | ﹤0.01% | 2506 |
|
|
2019
Q3 | $278K | Buy |
7,311
+1,946
| +36% | +$77.7K | ﹤0.01% | 2560 |
|
|
2019
Q2 | $233K | Sell |
5,365
-3,887
| -42% | -$165K | ﹤0.01% | 2517 |
|
|
2019
Q1 | $352K | Buy |
9,252
+8,291
| +863% | +$324K | ﹤0.01% | 2334 |
|
|
2018
Q4 | $41.3K | Sell |
961
-1,323
| -58% | -$61.8K | ﹤0.01% | 2805 |
|
|
2018
Q3 | $112K | Buy |
2,284
+191
| +9% | +$8.26K | ﹤0.01% | 2677 |
|
|
2018
Q2 | $67.1K | Sell |
2,093
-6,541
| -76% | -$226K | ﹤0.01% | 2990 |
|
|
2018
Q1 | $269K | Buy |
8,634
+376
| +5% | +$13.4K | ﹤0.01% | 2625 |
|
|
2017
Q4 | $377K | Buy |
8,258
+3,495
| +73% | +$139K | ﹤0.01% | 2636 |
|
|
2017
Q3 | $179K | Sell |
4,763
-239
| -5% | -$9.62K | ﹤0.01% | 2515 |
|
|
2017
Q2 | $239K | Buy |
5,002
+4,265
| +579% | +$198K | ﹤0.01% | 2344 |
|
|
2017
Q1 | $33.6K | Sell |
737
-431
| -37% | -$18.6K | ﹤0.01% | 2876 |
|
|
2016
Q4 | $37.7K | Sell |
1,168
-1,883
| -62% | -$62.8K | ﹤0.01% | 2953 |
|
|
2016
Q3 | $104K | Buy |
3,051
+1,607
| +111% | +$63K | ﹤0.01% | 2083 |
|
|
2016
Q2 | $48.7K | Buy |
1,444
+1,417
| +5,248% | +$69.6K | ﹤0.01% | 2312 |
|
|
2016
Q1 | $1.43K | Sell |
27
-3,506
| -99% | -$205K | ﹤0.01% | 2466 |
|
|
2015
Q4 | $271K | Sell |
3,533
-3,959
| -53% | -$224K | ﹤0.01% | 1314 |
|
|
2015
Q3 | $308K | Buy |
7,492
+4,460
| +147% | +$273K | ﹤0.01% | 1671 |
|
|
2015
Q2 | $214K | Buy |
3,032
+2,180
| +256% | +$172K | ﹤0.01% | 1682 |
|
|
2015
Q1 | $75.7K | Buy |
+852
| New | +$86.4K | ﹤0.01% | 1805 |
|
|
2014
Q4 | – | Sell |
-2,094
| Closed | -$203K | – | 2858 |
|
|
2014
Q3 | $203K | Buy |
2,094
+2,034
| +3,390% | +$198K | ﹤0.01% | 1866 |
|
|
2014
Q2 | $5.51K | Buy |
+60
| New | +$4.57K | ﹤0.01% | 2532 |
|
|
2014
Q1 | – | Sell |
-357
| Closed | -$20.5K | – | 3709 |
|
|
2013
Q4 | $20.5K | Sell |
357
-7,189
| -95% | -$378K | ﹤0.01% | 2237 |
|
|
2013
Q3 | $363K | Sell |
7,546
-2,197
| -23% | -$80.1K | ﹤0.01% | 1787 |
|
|
2013
Q2 | $283K | Buy |
+9,743
| New | +$282K | ﹤0.01% | 2053 |
|
Other funds holding PCRX
DPCM
BNP Paribas Financial Markets's PCRX Position: Q2 2026 in Review
BNP Paribas Financial Markets increased its Pacira BioSciences (PCRX) stake by 242% in Q2 2026, buying an estimated $994K and bringing the position to 59,385 shares worth $1.51M. The position accounts for ﹤0.01% of the portfolio, ranked #3030.
BNP Paribas Financial Markets first reported a position in PCRX in Q2 2013 and has held it in 50 quarters since. The position peaked at $6.54M in Q1 2020. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.
- BNP Paribas Financial Markets held 59,385 shares of Pacira BioSciences worth $1.51M as of Q2 2026.
- BNP Paribas Financial Markets bought 42,034 Pacira BioSciences shares in Q2 2026, an estimated $994K.
- Pacira BioSciences made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3030 holding.
- BNP Paribas Financial Markets first reported a position in Pacira BioSciences in Q2 2013 and has held it in 50 quarters since.
- BNP Paribas Financial Markets's Pacira BioSciences position peaked at $6.54M in Q1 2020.
- 253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.